Speakers - Sachs Associates

More documents

Recommendations

Info

CONTACTS Jack Barbut Chief Executive Officer David Slack Head of Corporate & Business Development ADDRESS 14 Chemin des Aulx 1228 Plan-les-Ouate Geneva Switzerland TELEPHONE +41 22 839 71 41 FAX +41 22 839 71 42 EMAIL jbarbut@novimmune.com dslack@novimmune.com YEAR FOUNDED 1999 NovImmune SA www.novimmune.com FINANCIAL SUMMARY Have raised 182M CHF from private investors including high-net worth individuals, corporate and private venture groups COMPANY PROFILE NovImmune is a life science enterprise with a proprietary next-generation antibody drug discovery platform and expertise in advancing drug candidates from bench to bedside. The Company is applying its capabilities to realize a vision of generating drugs that provide more robust benefit to patients by attacking the cause rather than symptoms of disease. NovImmune has established a balanced pipeline of first- and best-in-class preclinical and clinical drug candidates with a mix of both clinically validated and novel targets. • In 2009, received the European Biotechnica Award • In 2010, established Genentech/Roche partnership for NI-1401, anti-IL-17 drug candidate • In 2011, received Orphan Drug designation in Europe and the USA for, and in 2012 EUR 6 million FP7 grant from the European Commission for development of NI-0501 for HLH • Pursuing additional partnerships for its next-generation antibody platform as well as development and commercialization of selected drug candidates • Potential to independently bring selected drugs to the market for focused applications MANAGEMENT Eduard Holdener, M.D., Chairman Jack Barbut, Sc.D., Chief Executive Officer Cristina de Min, M.D., Chief Medical Officer Marie Kosco-Vilbois, Ph.D., Chief Scientific Officer David Slack, Head of Corporate & Business Development Nathalie Muller, Director of Legal Affairs t back :: next u WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS
CONTACTS General and Media Contact Emmanuelle Delabre Business Development Aram Mangasarian, PhD Chief Business Officer ADDRESS NOXXON Pharma AG Max-Dohrn-Strasse 8-10 10589 Berlin Germany TELEPHONE +49 30 726 247 0 Emmanuelle Delabre +49 30 726 247 100 FAX +49 30 726 247 225 EMAIL Noxxon@noxxon.com ibuchanan@noxxon.com edelabre@noxxon.com amangasarian@noxxon.com YEAR FOUNDED 1997 NOXXON Pharma AS www.noxxon.com FINANCIAL SUMMARY Since 2007 NOXXON has closed two financing rounds and raised approximately €72m Euros from venture capital investors. NOXXON’s major investors include Sofinnova Partners, TVM Capital, DEWB, Edmond de Rothschild Investment Partners, NGN Capital, Seventure, IBB Beteiligungsgesellschaft, Dow and GoodVent. COMPANY PROFILE NOXXON Pharma is a biopharmaceutical company pioneering the development of a new class of proprietary therapeutics called Spiegelmers, the chemically synthesized, non-immunogenic alternative to antibodies. NOXXON has a diversified portfolio of clinical stage Spiegelmer® therapeutics: NOX-E36 is an anti-CCL2 (MCP-1) Spiegelmer® currently in a Phase IIa study in diabetics with albuminuria. CCL2 is involved in recruitment of immune cells to the kidney in diabetic patients, a process which is associated with progression of chronic kidney disease. NOX-A12 is an anti-CXCL12 (SDF-1) Spiegelmer® that has begun two Phase IIa studies in hematological oncology indications (chronic lymphocytic leukemia and multiple myeloma). CXCL12 acts via its two receptors, CXCR4 and CXCR7, to mediate tumor invasion, metastasis and resistance to chemotherapy. NOX-H94 is an anti-hepcidin Spiegelmer® currently completing Phase I safety studies as well as a Phase I human pharmacodynamic study to assess its ability to prevent inflammation-induced hypoferremia. Hepcidin is the key regulator of iron metabolism and mediator of iron restriction in anemia of chronic disease via its interaction with the iron export protein, ferroportin. The Spiegelmer platform provides the company with powerful and unique discovery capabilities, which have generated a number of additional leads under preclinical investigation. Located in Berlin, Germany, NOXXON is a well-financed mature biotech company with a strong syndicate of international investors, approx. 60 employees and a highly experienced management team MANAGEMENT Senior Management Iain Buchanan, Chief Executive Officer Dr Matthias Baumann, Chief Medical Officer Dr Sven Klussmann, Chief Scientific Officer Aram Mangasarian, PhD, Chief Business Officer Supervisory Board Dr Walter Wenninger, Chairman of the Supervisory Board t back :: next u WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS
Page 1 and 2:
B I O T E C H I N E U R O P E I N V
Page 3 and 4:
Events Diary For regular updates, s
Page 5 and 6:
Speakers Alexey Eliseev, Managing D
Page 7 and 8:
Speakers Blake M. Paterson, Co-Foun
Page 9 and 10:
Speakers David Slack, Head of Corpo
Page 11 and 12:
Speakers Frank Grams, VP, Head Alli
Page 13 and 14:
Speakers Iain Buchanan, CEO, NOXXON
Page 15 and 16:
Speakers Juhani Lahdenperä, CEO, H
Page 17 and 18:
Speakers Marcel Zwaal, CBO, DCPrime
Page 19 and 20:
Speakers Paul Higham, Managing Dire
Page 21 and 22: Speakers Richard Goodfellow, CEO, S
Page 23 and 24: Speakers Søren Moller, Managing In
Page 25 and 26: CONTACT Robert F Burns, PhD Chief E
Page 27 and 28: CONTACTS Rostislav Raykov Chief Exe
Page 29 and 30: CONTACTS Vincent Charlon PhD, CEO Z
Page 31 and 32: CONTACTS Dr Bassam Damaj Chairman,
Page 33 and 34: CONTACT Carina Schmidt Chief Execut
Page 35 and 36: CONTACT Mr Richard Godfrey Chief Ex
Page 37 and 38: CONTACTS Tom Kronbach, PhD Chief Ex
Page 39 and 40: CONTACTS Andreas Caduff, PhD Chief
Page 41 and 42: CONTACTS Dr Blake Paterson Co-Found
Page 43 and 44: CONTACT Wolfgang Kintzel Chief Exec
Page 45 and 46: CONTACT Mike Romanos PhD Chief Exec
Page 47 and 48: CONTACT Harry Welten, MBA Chief Fin
Page 49 and 50: CONTACT Barbara Stiefel Office Mana
Page 51 and 52: CONTACTS Ana Martinez Assistant Jua
Page 53 and 54: CONTACTS Dr Rudi D Neirinckx Chief
Page 55 and 56: CONTACT Martin Bonde, PhD, BComm Ch
Page 57 and 58: CONTACT Benedikt Timmerman Chief Ex
Page 59 and 60: CONTACT Malcolm Weir Chief Executiv
Page 61 and 62: CONTACTS Mr Paul Higham Chief Execu
Page 63 and 64: CONTACTS Kevin FitzGerald Chief Ope
Page 65 and 66: CONTACT Roel Q. J Schaapveld, PhD,
Page 67 and 68: CONTACT Maaike Vogelezang Managemen
Page 69 and 70: CONTACT Tom Johnston Chief Executiv
Page 71: CONTACTS Aaron Powers President Dav
Page 75 and 76: CONTACTS Martin Welschof Chief Exec
Page 77 and 78: CONTACTS Carlos Buesa Chief Executi
Page 79 and 80: CONTACTS Nick McCooke Chief Executi
Page 81 and 82: CONTACT Dr Erik Buntinx Chief Execu
Page 83 and 84: CONTACT Michael Altorfer, Ph.D. Hea
Page 85 and 86: CONTACT Matthew B. Lehman Chief Ope
Page 87 and 88: ADDRESS Otto-Hahn-Strasse 15 D- 442
Page 89 and 90: CONTACT Dr Roman Schenk Chief Execu
Page 91 and 92: CONTACTS Dr Hans Fliri Chairman Sim
Page 93 and 94: CONTACTS Dr Raúl Insa Chief Execut
Page 95 and 96: CONTACT Dr Johanna Holldack, MD Chi
Page 97 and 98: CONTACT Eduardo Bravo (speaker) Man
Page 99 and 100: CONTACTS Piers Morgan Chief Financi
Page 101 and 102: CONTACT Jakob Knudsen Chief Executi
Page 103 and 104: CONTACTS Dr Sonja Reingruber Chief
Page 105 and 106: Supporting Organisations Citigate D
Page 107 and 108: Supporting Organisations Life Scien
Page 109 and 110: Supporting Organisations Swiss Biot
Page 111 and 112: Supporting Organisations Torreya Pa
Page 113: B I O T E C H I N E U R O P E I N V
show all

Speakers - Sachs Associates

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?